{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Korzun T"],"funding":["NCI NIH HHS"],"pagination":["e2204436"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9633376"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["18(44)"],"pubmed_abstract":["This study presents the first messenger RNA (mRNA) therapy for metastatic ovarian cancer and cachexia-induced muscle wasting based on lipid nanoparticles that deliver follistatin (FST) mRNA predominantly to cancer clusters following intraperitoneal administration. The secreted FST protein, endogenously synthesized from delivered mRNA, efficiently reduces elevated activin A levels associated with aggressive ovarian cancer and associated cachexia. By altering the cancer cell phenotype, mRNA treatment prevents malignant ascites, delays cancer progression, induces the formation of solid tumors, and preserves muscle mass in cancer-bearing mice by inhibiting negative regulators of muscle mass. Finally, mRNA therapy provides synergistic effects in combination with cisplatin, increasing the surviv"],"journal":["Small (Weinheim an der Bergstrasse, Germany)"],"pubmed_title":["Nanoparticle-Based Follistatin Messenger RNA Therapy for Reprogramming Metastatic Ovarian Cancer and Ameliorating Cancer-Associated Cachexia."],"pmcid":["PMC9633376"],"funding_grant_id":["R37 CA234006","R01 CA237569"],"pubmed_authors":["Brody JR","Sundaram S","Kim J","Diba P","Sahay G","Pejovic T","Schumann C","Eygeris Y","Park Y","Taratula OR","Levasseur PR","Rebola KGO","Patel S","Olson B","Norgard M","Demessie AA","Zhu X","Marks DL","Korzun T","Grigoriev V","Moses AS","Taratula O"],"additional_accession":[]},"is_claimable":false,"name":"Nanoparticle-Based Follistatin Messenger RNA Therapy for Reprogramming Metastatic Ovarian Cancer and Ameliorating Cancer-Associated Cachexia.","description":"This study presents the first messenger RNA (mRNA) therapy for metastatic ovarian cancer and cachexia-induced muscle wasting based on lipid nanoparticles that deliver follistatin (FST) mRNA predominantly to cancer clusters following intraperitoneal administration. The secreted FST protein, endogenously synthesized from delivered mRNA, efficiently reduces elevated activin A levels associated with aggressive ovarian cancer and associated cachexia. By altering the cancer cell phenotype, mRNA treatment prevents malignant ascites, delays cancer progression, induces the formation of solid tumors, and preserves muscle mass in cancer-bearing mice by inhibiting negative regulators of muscle mass. Finally, mRNA therapy provides synergistic effects in combination with cisplatin, increasing the surviv","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2025-05-29T21:44:09.046Z","creation":"2025-05-29T21:44:09.046Z"},"accession":"S-EPMC9633376","cross_references":{"pubmed":["36098251"],"doi":["10.1002/smll.202204436"]}}